Ranolazine dispersible tablet and preparation method thereof

A technology of ranolazine and dispersible tablets, which is applied in the field of ranolazine dispersible tablets and its preparation, which can solve the problems of affecting cardiac electrical conduction and QT interval prolongation, and achieve the effects of less side effects, less intestinal residues, and convenient administration

Inactive Publication Date: 2018-05-08
FOSHAN TENGRUI MEDICINE TECH CO LTD
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Studies have shown that it can partially inhibit fatty acid oxidation, but at the same time it can also affect the electrical conduction of the heart, causing dose-related QT interval prolongation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Ranolazine dispersible tablet and preparation method thereof
  • Ranolazine dispersible tablet and preparation method thereof
  • Ranolazine dispersible tablet and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment l

[0020] prescription:

[0021]

[0022] Preparation:

[0023] (1) Mix ranolazine powder (200 mesh) and sucrose powder (150 mesh) in equal increments to obtain mixture A;

[0024] (2) Pass the remaining auxiliary materials through a 200-mesh sieve, and mix them uniformly in equal increments to obtain mixture B;

[0025] (3) Mix mixture A and mixture B uniformly according to the method of equal increase, and then directly compress into tablets.

Embodiment 2

[0027] prescription:

[0028]

[0029] Preparation:

[0030] (1) Mix ranolazine powder (200 mesh) and lactose powder (150 mesh) in equal increments to obtain mixture A;

[0031] (2) Pass the remaining auxiliary materials through a 200-mesh sieve, and mix them uniformly in equal increments to obtain mixture B;

[0032] (3) Mix mixture A and mixture B uniformly according to the method of equal increase, and then directly compress into tablets.

Embodiment 3

[0034] prescription:

[0035]

[0036] Preparation:

[0037] (1) Mix ranolazine powder (200 mesh) and lactose powder (150 mesh) in equal increments to obtain mixture A;

[0038] (2) Pass the remaining auxiliary materials through a 200-mesh sieve, and mix them uniformly in equal increments to obtain mixture B;

[0039] (3) Mix mixture A and mixture B uniformly according to the method of equal increase, and then directly compress into tablets.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a ranolazing dispersible tablet, which is prepared by the following steps: taking ranolazing as a raw material and adding ingredients. The ranolazing dispersible tablet provided by the invention has the advantages that the disintegration is quick, the absorption is quick, the bioavailability is high, the medicine-taking is convenient, the residue of the intestinal tract isless, the side effect is less, the taste is sweet and fragrant and the patient medication compliance is especially easy to be improved.

Description

technical field [0001] The invention relates to a new dosage form of ranolazine, in particular to ranolazine dispersible tablets and a preparation method thereof. Background technique [0002] Ranolazine has anti-angina pectoris and anti-myocardial ischemia effects, but its specific mechanism of action is still unclear. Studies have shown that it can partially inhibit fatty acid oxidation, but at the same time it can also affect the electrical conduction of the heart, causing dose-related QT interval prolongation. Ranolazine is limited to the use of long-acting nitrates, calcium ion channel blockers and β2 receptor blockers and other anti-angina drugs ineffective. Clinical trials have shown that the effect of ranolazine on male patients is better than that of women, and the long-term [0003] Adverse reactions such as dizziness, headache, constipation and nausea may occur if taken for a long time. [0004] Ranolazine, a new chemical entity, is the first FDA-approved drug ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/20A61K47/20A61K31/495A61P9/10
CPCA61K9/2013A61K31/495
Inventor 欧泽桂
Owner FOSHAN TENGRUI MEDICINE TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap